New oral drug could replace steroids for severe colitis Flare-Ups

NCT ID NCT07502339

Not yet recruiting Disease control Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether the oral medication upadacitinib can safely treat acute severe ulcerative colitis in hospitalized adults without using steroids. Fifty participants will take upadacitinib daily during their hospital stay and be monitored for up to a year. The goal is to see if this drug reduces the need for surgery or rescue treatments compared to past standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: upadacitinib (oral JAK inhibitor)
What this could lead to: If successful, this could offer a steroid-free, oral treatment option for hospitalized patients with severe ulcerative colitis, potentially reducing the need for surgery or rescue therapy.
What could go wrong: This is a small, early-phase 4 study with only 50 participants and no placebo group. Results may not apply to all patients, and side effects of upadacitinib include infection risk and blood clots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UC - ULCERATIVE COLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UC - ULCERATIVE COLITIS

Contacts and locations

Locations

UCSF Medical Center

San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.